Delving into the Latest Updates on Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. with Synapse

Overview

一项在既往接受过至少 1 线治疗的复发性或难治性多发性骨髓瘤受试者中比较Talquetamab（皮下注射）联合达雷妥尤单抗（皮下注射）和泊马度胺（Tal-DP）或Talquetamab（皮下注射）联合达雷妥尤单抗（皮下注射）（Tal-D）与达雷妥尤单抗（皮下注射）、泊马度胺和地塞米松（DPd）的III 期、随机研究

[Translation] A Phase III, randomized study comparing talquetamab (SC) plus daratumumab (SC) and pomalidomide (Tal-DP) or talquetamab (SC) plus daratumumab (SC) (Tal-D) versus daratumumab (SC), pomalidomide, and dexamethasone (DPd) in subjects with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy

本试验目的是分别比较Talquetamab 皮下给药联用达雷妥尤单抗皮下给药和泊马度胺（Tal-DP；A组）、Talquetamab 皮下给药联用达雷妥尤单抗皮下给药（Tal-D；C组）与达雷妥尤单抗皮下给药联用泊马度胺和地塞米松（DPd；B组）在复发或难治性多发性骨髓瘤患者中的疗效

[Translation]

The aim of this trial was to compare the efficacy of subcutaneous talquetamab plus subcutaneous daratumumab and pomalidomide (Tal-DP; group A), subcutaneous talquetamab plus subcutaneous daratumumab (Tal-D; group C), and subcutaneous daratumumab plus pomalidomide and dexamethasone (DPd; group B) in patients with relapsed or refractory multiple myeloma.

Start Date07 Feb 2023

Sponsor / Collaborator

Catalent CTS LLC

[+9]

100 Clinical Results associated with Catalent (Shanghai) Clinical Trial Supplies Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Catalent (Shanghai) Clinical Trial Supplies Co., Ltd.

Login to view more data

100 Deals associated with Catalent (Shanghai) Clinical Trial Supplies Co., Ltd.

Login to view more data

100 Translational Medicine associated with Catalent (Shanghai) Clinical Trial Supplies Co., Ltd.

Login to view more data